Phase II study of bendamustine, bortezomib and dexamethasone as second-line treatment for elderly patients with multiple myeloma: the Intergroupe Francophone du Myelome 2009-01 trial

Documenti analoghi

• Otolog Hematopoetik Kök Hücre Nakli Yapılan Multiple Myelom Hastalarında Kemik İliği Fibrozisinin Nakil Sonuçlarına Etkisi
  di: Ebru Kılıç Güneş, et al.
  Pubblicazione: (2024-10-01)
• Phase II study of bendamustine, bortezomib and dexamethasone as second-line treatment for elderly patients with multiple myeloma: the Intergroupe Francophone du Myelome 2009-01 trial
  di: Philippe Rodon, et al.
  Pubblicazione: (2015-02-01)
• 35 years of academic trials focusing on high-dose therapy and autologous stem cell transplantation: the Intergroupe Francophone du Myélome (IFM) experience
  di: Philippe Moreau, et al.
  Pubblicazione: (2025-10-01)
• P891: IXAZOMIB AND DARATUMUMAB WITHOUT DEXAMETHASONE (I-DARA) IN ELDERLY FRAIL RRMM PATIENTS: RESULTS OF THE MULTICENTER PHASE 2 STUDY (IFM 2018-02) OF THE INTERGROUPE FRANCOPHONE DU MYÉLOME (IFM).
  di: Margaret Macro, et al.
  Pubblicazione: (2023-08-01)
• P929: IXAZOMIB AND DARATUMUMAB WITHOUT DEXAMETHASONE (I-DARA) IN ELDERLY FRAIL RELAPSING MYELOMA (RRMM) PATIENTS: RESULTS OF THE PHASE 2 STUDY IFM 2018-02 OF THE INTERGROUPE FRANCOPHONE DU MYELOME (IFM).
  di: M. Macro, et al.
  Pubblicazione: (2022-06-01)